Zheng Quan Shi Bao Wang·2025-08-22 02:53Core Insights - The European Commission has approved a new film-coated tablet formulation of BeiGene's drug Brukinsa (Zebutinib) for all locally approved indications [1] - The tablet formulation is set to gradually replace the capsule formulation in the EU market starting from October 2025, aiming to meet clinical treatment needs and enhance patient convenience [1] Company Summary - BeiGene's Brukinsa will transition to a tablet form in the EU, which is expected to improve patient adherence and ease of use [1] - The approval reflects BeiGene's commitment to addressing patient needs and optimizing treatment options [1] Industry Summary - The shift from capsule to tablet formulation indicates a trend towards more patient-friendly drug delivery methods in the pharmaceutical industry [1] - This change may influence market dynamics and competitive positioning within the oncology treatment sector [1]